Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308
- Authors:
- Shaghayegh Nouruzi
- Fraser Johnson
- Sahil Kumar
- Olena Sivak
- Nakisa Tabrizian
- Milla Koistinaho
- Anu Muona
- Amina Zoubeidi
-
Affiliations: Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada, Aranda Pharma Ltd., 70210 Kuopio, Finland - Published online on: August 7, 2024 https://doi.org/10.3892/or.2024.8791
- Article Number: 132
-
Copyright: © Nouruzi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
|
Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, Bray F, Brawley O, Luckenbaugh AN, Mucci L, et al: 2022 Update on prostate cancer epidemiology and risk factors-a systematic review. Eur Urol. 84:191–206. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W, Cao G, Wu F, Wang Y, Liu Z, Hu H and Xu K: Global burden of prostate cancer and association with socioeconomic status, 1990-2019: A systematic analysis from the global burden of disease study. J Epidemiol Glob Health. 13:407–421. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
World Health Organization (WHO), . Prostate cancer statistics. WHO; Geneva: 2024 | |
|
Heinlein CA and Chang C: Androgen receptor in prostate cancer. Endocr Rev. 25:276–308. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Seikkula H, Boström PJ, Seppä K, Pitkäniemi J, Malila N and Kaipia A: Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation. BMC Urol. 20:252020. View Article : Google Scholar : PubMed/NCBI | |
|
Kokorovic A, So AI, Serag H, French C, Hamilton RJ, Izard JP, Nayak JG, Pouliot F, Saad F, Shayegan B, et al: Canadian urological association guideline on androgen deprivation therapy: Adverse events and management strategies. Can Urol Assoc J. 15:E307–E322. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Vellky JE and Ricke WA: Development and prevalence of castration-resistant prostate cancer subtypes. Neoplasia. 22:566–575. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kirby M, Hirst C and Crawford ED: Characterising the castration-resistant prostate cancer population: A systematic review. Int J Clin Pract. 65:1180–1192. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 367:1187–1197. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 364:1995–2005. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Nevedomskaya E, Baumgart SJ and Haendler B: Recent advances in prostate cancer treatment and drug discovery. Int J Mol Sci. 19:13592018. View Article : Google Scholar : PubMed/NCBI | |
|
Mateo J, Smith A, Ong M and de Bono JS: Novel drugs targeting the androgen receptor pathway in prostate cancer. Cancer Metastasis Rev. 33:567–579. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Crona DJ, Milowsky MI and Whang YE: Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. Clin Pharmacol Ther. 98:582–589. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, et al: Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 116:11428–11436. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, et al: Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 155:1309–1322. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, et al: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 371:1028–1038. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, et al: ARv7 represses tumor-suppressor genes in castration-resistant prostate cancer. Cancer Cell. 35:401–413.e6. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, Moon M, Maneval EC, Chen I, Darimont B and Hager JH: A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 3:1020–1029. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Einstein DJ, Arai S and Balk SP: Targeting the androgen receptor and overcoming resistance in prostate cancer. Curr Opin Oncol. 31:175–182. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Takeda DY, Spisák S, Seo JH, Bell C, O'Connor E, Korthauer K, Ribli D, Csabai I, Solymosi N, Szállási Z, et al: A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer. Cell. 174:422–432.e13. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, et al: Genomic hallmarks and structural variation in metastatic prostate cancer. Cell. 175:8892018. View Article : Google Scholar : PubMed/NCBI | |
|
Viswanathan SR, Ha G, Hoff AM, Wala JA, Carrot-Zhang J, Whelan CW, Haradhvala NJ, Freeman SS, Reed SC, Rhoades J, et al: Structural alterations driving castration- resistant prostate cancer revealed by linked-read genome sequencing. Cell. 174:433–447.e19. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, et al: Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 32:474–489.e6. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li Q, Deng Q, Chao HP, Liu X, Lu Y, Lin K, Liu B, Tang GW, Zhang D, Tracz A, et al: Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat Commun. 9:36002018. View Article : Google Scholar : PubMed/NCBI | |
|
He Y, Wei T, Ye Z, Orme JJ, Lin D, Sheng H, Fazli L, Jeffrey Karnes R, Jimenez R, Wang L, et al: A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. Nat Commun. 12:15212021. View Article : Google Scholar : PubMed/NCBI | |
|
Davies A, Nouruzi S, Ganguli D, Namekawa T, Thaper D, Linder S, Karaoğlanoğlu F, Omur ME, Kim S, Kobelev M, et al: An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nat Cell Biol. 23:1023–1034. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, Nykänen PS, Törmäkangas OP, Palvimo JJ and Kallio PJ: Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 5:120072015. View Article : Google Scholar : PubMed/NCBI | |
|
Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, et al: The master neural transcription factor BRN2 Is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 7:54–71. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Yeh S, Kang HY, Miyamoto H, Nishimura K, Chang HC, Ting HJ, Rahman M, Lin HK, Fujimoto N, Hu YC, et al: Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells. Endocrine. 11:195–202. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M and Gingeras TR: STAR: Ultrafast universal RNA-seq aligner. Bioinformatics. 29:15–21. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL and Pachter L: Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and cufflinks. Nat Protoc. 7:562–578. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Love MI, Huber W and Anders S: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Z, Lan X, Thomas-Ahner JM, Wu D, Liu X, Ye Z, Wang L, Sunkel B, Grenade C, Chen J, et al: Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer. EMBO J. 34:502–516. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bittencourt SA: FastQC: A quality control tool for high throughput sequence data. Babraham Bioinformatics. 2010. | |
|
Li H and Durbin R: Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 25:1754–1760. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G and Durbin R; 1000 Genome Project Data Processing Subgroup, : The sequence alignment/map format and SAMtools. Bioinformatics. 25:2078–2079. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W and Liu XS: Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9:R1372008. View Article : Google Scholar : PubMed/NCBI | |
|
Ramirez F, Ryan DP, Grüning B, Bhardwaj V, Kilpert F, Richter AS, Heyne S, Dündar F and Manke T: deepTools2: A next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 44:W160–W165. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Quinlan AR and Hall IM: BEDTools: A flexible suite of utilities for comparing genomic features. Bioinformatics. 26:841–842. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Reimand J, Arak T, Adler P, Kolberg L, Reisberg S, Peterson H and Vilo J: g:Profiler-a web server for functional interpretation of gene lists (2016 update). Nucleic Acids Res. 44:W83–W89. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Maffey AH, Ishibashi T, He C, Wang X, White AR, Hendy SC, Nelson CC, Rennie PS and Ausió J: Probasin promoter assembles into a strongly positioned nucleosome that permits androgen receptor binding. Mol Cell Endocrinol. 268:10–19. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Namekawa T, Ikeda K, Horie-Inoue K and Inoue S: Application of prostate cancer models for preclinical study: Advantages and limitations of cell lines, patient-derived xenografts, and three-dimensional culture of patient-derived cells. Cells. 8:742019. View Article : Google Scholar : PubMed/NCBI | |
|
Borgmann H, Lallous N, Ozistanbullu D, Beraldi E, Paul N, Dalal K, Fazli L, Haferkamp A, Lejeune P, Cherkasov A and Gleave ME: Moving towards precision urologic oncology: Targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201). Eur Urol. 73:4–8. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Waltering KK, Urbanucci A and Visakorpi T: Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol Cell Endocrinol. 360:38–43. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, Yuan J, Kovats SG, Kim S, Cooke VG, et al: An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 3:1030–1043. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu H, Wang L, Tian J, Li J and Liu H: Molecular dynamics studies on the enzalutamide resistance mechanisms induced by androgen receptor mutations. J Cell Biochem. 118:2792–2801. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO and Mulder E: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 173:534–540. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Dai C, Heemers H and Sharifi N: Androgen signaling in prostate cancer. Cold Spring Harb Perspect Med. 7:a0304522017. View Article : Google Scholar : PubMed/NCBI | |
|
Eder IE, Culig Z, Putz T, Nessler-Menardi C, Bartsch G and Klocker H: Molecular biology of the androgen receptor: From molecular understanding to the clinic. Eur Urol. 40:241–251. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Smith DF and Toft DO: Minireview: The intersection of steroid receptors with molecular chaperones: Observations and questions. Mol Endocrinol. 22:2229–2240. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Verrijdt G, Haelens A and Claessens F: Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression. Mol Genet Metab. 78:175–185. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao J, Zhao Y, Wang L, Zhang J, Karnes RJ, Kohli M, Wang G and Huang H: Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer. Oncotarget. 7:38551–38565. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Li K, Guo Y, Yang X, Zhang Z, Zhang C and Xu Y: ELF5-mediated AR activation regulates prostate cancer progression. Sci Rep. 7:427592017. View Article : Google Scholar : PubMed/NCBI | |
|
Rodriguez-Vida A, Galazi M, Rudman S, Chowdhury S and Sternberg CN: Enzalutamide for the treatment of metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 9:3325–3339. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 368:138–148. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, et al: Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 13:983–992. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS and Montgomery RB: Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 17:5913–5925. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME and Nelson CC: Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68:6407–6415. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD and Nelson PS: Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res. 68:4447–4454. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lallous N, Dalal K, Cherkasov A and Rennie PS: Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer. Int J Mol Sci. 14:12496–12519. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Nouruzi S, Ganguli D, Tabrizian N, Kobelev M, Sivak O, Namekawa T, Thaper D, Baca SC, Freedman ML, Aguda A, et al: ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer. Nat Commun. 13:22822022. View Article : Google Scholar : PubMed/NCBI | |
|
Tabrizian N, Nouruzi S, Cui CJ, Kobelev M, Namekawa T, Lodhia I, Talal A, Sivak O, Ganguli D and Zoubeidi A: ASCL1 is activated downstream of the ROR2/CREB signaling pathway to support lineage plasticity in prostate cancer. Cell Rep. 42:1129372023. View Article : Google Scholar : PubMed/NCBI | |
|
Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker A, Arnold J, et al: The role of lineage plasticity in prostate cancer therapy resistance. Clin Cancer Res. 25:6916–6924. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, et al: Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 22:298–305. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, et al: Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study. J Clin Oncol. 36:2492–2503. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Linder S, Hoogstraat M, Stelloo S, Eickhoff N, Schuurman K, de Barros H, Alkemade M, Bekers EM, Severson TM, Sanders J, et al: Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer toward androgen independence. Cancer Discov. 12:2074–2097. 2022. View Article : Google Scholar : PubMed/NCBI |
